Folate in Depression: Efficacy, Safety, Differences in Formulations, and Clinical Issues

Maurizio Fava, MD, and David Mischoulon, MD, PhD

Supplementation with folate may help reduce depressive symptoms. Folate, a naturally occurring B vitamin, is needed in the brain for the synthesis of norepinephrine, serotonin, and dopamine. Three forms of folate are commonly used: folic acid, 5-methyltetrahydrofolate (5-MTHF) (also known as methylfolate and l-methylfolate), and folinic acid. Some forms may be more bioavailable than others in patients with a genetic polymorphism and in those who take particular medications or use alcohol. Folic acid augmentation in depressed patients may reduce residual symptoms. The 5-MTHF formulation indicated efficacy as adjunctive therapy or monotherapy in reducing depressive symptoms in patients with normal and low folate levels, improving cognitive function and reducing depressive symptoms in elderly patients with dementia and folate deficiency, and reducing depressive and somatic symptoms in patients with depression and alcoholism. Adjunctive folinic acid reduced depressive symptoms in patients who were partially responsive or nonresponsive to a selective serotonin reuptake inhibitor. Evidence for the efficacy of folate in improving cognitive symptoms is equivocal, but most studies used folic acid. Although the studies reviewed have limitations and, historically, concerns have been raised about the role of folate in increasing cancer risk, masking B12 deficiency, and worsening depressive symptoms, folate is generally well tolerated, and 5-MTHF may be less likely to incur some of these risks. Several forms of folate appear to be safe and efficacious in some individuals with major depressive disorder, but more information is needed about dosage and populations most suited to folate therapy.

From the Department of Psychiatry, Harvard Medical School and Massachusetts General Hospital, Boston.

This article is derived from the planning teleconference series “The Use of Complementary and Alternative Medicines to Achieve Remission in Major Depressive Disorder,” which was held in May 2009 and supported by an educational grant from Pamlab, LLC.

Financial disclosure appears at the end of the article.

Corresponding author: Maurizio Fava, MD, Massachusetts General Hospital, 55 Fruit Street, Bulfinch 351, Boston, MA 02114 (mfava@partners.org).

doi:10.4088/JCP.8157su1c.03

© Copyright 2009 Physicians Postgraduate Press, Inc.
in the intestines and liver to become l-methylfolate (see Figure 1), a biologically active form of folate that can cross the blood-brain barrier and activate the enzymes that synthesize dopamine, norepinephrine, and serotonin.12

The enzyme dihydrofolate reductase (DHFR) catalyzes the transformation of folic acid into dihydrofolate (see Figure 1). Patients who take lamotrigine and other medications that are inhibitors of DHFR may benefit from treatment with a form of folate that does not require DHFR (Table 2).11 Folic acid and 5-MTHF differ from folic acid in that they do not require DHFR for transformation into an active form of folate.

The enzyme methylenetetrahydrofolate reductase (MTHFR) is needed for the one-carbon metabolism of folic acid and folinic acid (see Figure 1); however, this enzyme is affected by the C677T polymorphism, a genetic variation that is common in individuals with depression15 and can impair the transformation into l-methylfolate.12 In patients with this genetic polymorphism, 5-MTHF may be more suitable than other forms of folate in reducing depressive symptoms because it does not need MTHFR to cross the blood-brain barrier.

STUDIES OF FOLATE IN DEPRESSION

Folic Acid

Two randomized, controlled studies16,17 have examined folic acid as augmentation therapy for depression. In a study16 of lithium and folate, 75 patients (53 with unipolar depression, 17 with bipolar depression, and 4 with schizoaffective disorder) who were being treated with lithium received 200 µg/d of folate or placebo for 1 year. Patients whose plasma folate was 13 ng/mL or above at endpoint had a >40% reduction in Affective Morbidity Index scores over the 1-year trial period. Among patients with unipolar depression who received folate, a small but significant reduction in scores on the Beck Depression Inventory (BDI) occurred during the trial (P < .02), whereas those receiving placebo experienced a small increase in BDI scores. Augmentation with folate produced no significant changes in side effect scores. This study suggests that folate may reduce residual symptoms of depression, particularly in individuals with low folate levels.

In the second study,17 127 patients with first-episode depression were given 20 mg/d of the selective serotonin reuptake inhibitor (SSRI) fluoxetine and were randomly assigned to receive augmentation with either 500 µg/d of folic acid or placebo for 10 weeks. Fewer patients taking folic acid experienced side effects compared with those taking placebo (12.9% vs 29.7%, respectively). As shown in Figure 2, a significantly greater percentage of women who received folic acid, compared with those who received placebo, responded (P < .005). In men, folic acid did not separate from placebo as an augmenting agent. The 500-µg/d dose may have been insufficient for men, or perhaps 5-MTHF would have been a more appropriate supplement than folic acid since the MTHFR C677T polymorphism tends to be overrepresented (P = .03) among patients with depression,19 impeding bioavailability.

Methyltetrahydrofolate

Five studies have examined 5-MTHF augmentation or monotherapy in depression; 3 were randomized, controlled trials,18–20 and 2 were open studies.21,22 Godfrey and colleagues18 studied 123 patients with major depression or schizophrenia in a double-blind, placebo-controlled trial, and 41 of the patients (33%) were found to have a definite or borderline folate deficiency. These patients received either 15 mg/d of methylfolate or placebo in addition to standard psychotropic medications for 6 months. Among patients with depression (n = 24), Hamilton Depression Rating Scale (HDRS) scores were somewhat reduced in those who received methylfolate, while scores increased in those who received placebo, and this difference was apparent at both 3 months and 6 months, although changes were not significant.

A double-blind study19 compared 50 mg/d of methylfolate monotherapy with 150 mg/d of amitriptyline in 31 outpatients with moderate depression and mostly normal folate levels over 6 weeks, after a 2-week placebo run-in phase to eliminate placebo responders. Three patients withdrew because of common side effects of amitriptyline. Similar response rates were found between the groups, but, among those who took methylfolate, the responders showed increased folate levels compared with nonresponders.

Monotherapy with 5-MTHF was compared with trazodone in a double-blind study20 of elderly depressed patients with mild-to-moderate dementia and normal folate levels. Patients received a 2-week placebo run-in, and the 96 placebo nonresponders were then randomly assigned to 50 mg/d of 5-MTHF or 100 mg/d of trazodone for 8 weeks. No patients withdrew because of adverse events, but 1 patient

FOR CLINICAL USE

◆ Consider folate supplementation from the start of treatment in patients with depression and low or normal folate levels.
◆ Folate appears to be well tolerated.
◆ Some forms of folate may be more effective than others in particular patient populations, but more rigorous study is needed.
treated with trazodone reported vertigo and blurred vision; otherwise, the treatments were safe and well tolerated. Partial to complete response to antidepressant treatment was seen in a greater percentage of those who received 5-MTHF than in those who received trazodone (Figure 3).

In an open study,21 20 patients over 60 years old with depressive disorder received 50 mg/d of MTHF monotherapy for 6 weeks. Only 2 patients had low folate levels at baseline. Over the 6-week period, mean HDRS-21 scores decreased from 34.8 to 9.9 at endpoint. A statistically significant improvement was seen in HDRS scores from baseline at week 1 ($P < .01$) and became more robust over the 6 weeks ($P < .0001$).

Overall, the response rate (≥ 50% decrease in HDRS score) for MTHF was 81%. In these individuals, MTHF showed efficacy and produced rapid improvement in depressive symptoms.

In another open study22 of methylfolate monotherapy, 36 inpatients with depression and chronic alcoholism were followed for 4 weeks, during which they were treated with 30 mg tid methylfolate. Alcohol abuse can lower folate levels (see Table 2).11 No adverse events were reported, and all 36 patients completed the study. Mean HRSD-21 scores fell from 35.27 at baseline to 18.83 at endpoint ($P < .01$) and were statistically significant versus baseline by week 2. Significant ($P < .01$) improvement in well-being and reduction in fatigue and pain from baseline to week 4, according to Visual Analog Scales, were also reported. Sleep improved but the changes were not statistically significant.

### Folinic Acid

Folinic acid, or leucovorin, is an adjuvant chemotherapy agent. A group of 22 normofolatemic adults with MDD and partial or nonresponse to an SSRI after at least 4 weeks of treatment were treated with adjunctive folinic acid in an 8-week open, prospective trial.23 Treatment with folinic acid (15–30 mg/d) was well tolerated. Among completers and the intent-to-treat group, mean HDRS-17 scores decreased significantly ($P < .01$) from baseline to endpoint (Figure 4). Among completers, 31% achieved response and 19% achieved remission.

### FOLATE AUGMENTATION FOR COGNITION

Folate has a potential role in depression treatment as an augmentation therapy to reduce cognitive symptoms. Difficulties with memory, concentration, or alertness are

---

### Table 1. Selected Food Sources of Folate and Folic Acid

<table>
<thead>
<tr>
<th>Food</th>
<th>Micrograms (μg)</th>
<th>Daily Value (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breakfast cereals fortified with 100% of the DV, ¾ cup</td>
<td>400</td>
<td>100</td>
</tr>
<tr>
<td>Beef liver, cooked, braised, ¾ ounce</td>
<td>185</td>
<td>45</td>
</tr>
<tr>
<td>Cowpeas (blackeyes), immature, cooked, boiled, ¼ cup</td>
<td>105</td>
<td>25</td>
</tr>
<tr>
<td>Breakfast cereals fortified with 25% of the DV, ¾ cup</td>
<td>100</td>
<td>25</td>
</tr>
<tr>
<td>Spinach, frozen, cooked, boiled, ¼ cup</td>
<td>100</td>
<td>25</td>
</tr>
<tr>
<td>Great Northern beans, boiled, ¼ cup</td>
<td>90</td>
<td>20</td>
</tr>
<tr>
<td>Asparagus, boiled, 4 spears</td>
<td>85</td>
<td>20</td>
</tr>
<tr>
<td>Rice, white, long-grain, parboiled, enriched, cooked, ¼ cup</td>
<td>65</td>
<td>15</td>
</tr>
<tr>
<td>Vegetarian baked beans, canned, 1 cup</td>
<td>60</td>
<td>15</td>
</tr>
<tr>
<td>Spinach, raw, 1 cup</td>
<td>60</td>
<td>15</td>
</tr>
<tr>
<td>Green peas, frozen, boiled, ½ cup</td>
<td>50</td>
<td>15</td>
</tr>
<tr>
<td>Broccoli, chopped, frozen, cooked, ½ cup</td>
<td>50</td>
<td>15</td>
</tr>
<tr>
<td>Egg noodles, cooked, enriched, ½ cup</td>
<td>50</td>
<td>15</td>
</tr>
<tr>
<td>Broccoli, raw, 2 spears (each 5 inches long)</td>
<td>45</td>
<td>10</td>
</tr>
<tr>
<td>Avocado, raw, all varieties, sliced, ½ cup sliced</td>
<td>45</td>
<td>10</td>
</tr>
<tr>
<td>Peanuts, all types, dry roasted, 1 ounce</td>
<td>40</td>
<td>10</td>
</tr>
<tr>
<td>Lettuce, Romaine, shredded, ¼ cup</td>
<td>40</td>
<td>10</td>
</tr>
<tr>
<td>Wheat germ, crude, 2 tablespoons</td>
<td>40</td>
<td>10</td>
</tr>
<tr>
<td>Tomato juice, canned, 6 ounces</td>
<td>35</td>
<td>10</td>
</tr>
<tr>
<td>Orange juice, chilled, includes concentrate, ¼ cup</td>
<td>35</td>
<td>10</td>
</tr>
<tr>
<td>Turnip greens, frozen, cooked, ½ cup</td>
<td>30</td>
<td>8</td>
</tr>
<tr>
<td>Orange, all commercial varieties, fresh, 1 small</td>
<td>30</td>
<td>8</td>
</tr>
<tr>
<td>Bread, white, 1 slice</td>
<td>25</td>
<td>6</td>
</tr>
<tr>
<td>Bread, whole wheat, 1 slice</td>
<td>25</td>
<td>6</td>
</tr>
<tr>
<td>Egg, whole, raw, fresh, 1 large</td>
<td>25</td>
<td>6</td>
</tr>
<tr>
<td>Cantaloupe, raw, ¼ medium</td>
<td>25</td>
<td>6</td>
</tr>
<tr>
<td>Papaya, raw, ½ cup cubes</td>
<td>25</td>
<td>6</td>
</tr>
<tr>
<td>Banana, raw, 1 medium</td>
<td>20</td>
<td>6</td>
</tr>
</tbody>
</table>

---

*Reprinted from the National Institutes of Health Office of Dietary Supplements.11

*The Daily Value (DV) for folate is 400 micrograms (μg). The Daily Value (%) listed in the table indicates the percentage of the Daily Value provided in one serving.

*Fortified with folic acid as part of the Folate Fortification Program.

---

**Figure 1. Metabolic Steps Required for 3 Folate Formulations to Cross the Blood-Brain Barrier**

- **Folic Acid**
  - Converted by DHFR, which is inhibited by lamotrigine, methotrexate, and other drugs

- **Dihydrofolate (DFH)** (folate from food)

- **Tetrahydrofolate (THF)**

- **Folinic Acid**
  - Converted by MTHFR, which is affected by C677T polymorphism

- **L-Methylfolate**
  - Helps form BH4, which is needed to synthesize dopamine, norepinephrine, and serotonin

---

**Abbreviations:** BH4 = tetrahydrobiopterin, DHFR = dihydrofolate reductase, MTHFR = methylenetetrahydrofolate reductase.
common in people with MDD; more than 30% of patients who responded to antidepressants were found to have such difficulties.5

In elderly patients, poor cognitive function and dementia were found to be associated with low folate status.4 Folate inadequacy in adults is associated with high blood levels of the amino acid homocysteine, a marker that has been linked with risk of arterial disease, dementia, and Alzheimer’s disease.24 In theory, supplementation with folate should lower plasma homocysteine and improve cognition. The double-blind study20 that compared 5-MTHF monotherapy with trazodone in elderly depressed patients with mild-to-moderate dementia and normal folate levels examined not only depressive symptoms but also cognitive functions. A higher proportion of patients treated with 5-MTHF demonstrated improvement of at least 10% in immediate recall than those treated with trazodone (53% vs 37%; \(P < .05\)); improvement in immediate recall was significantly improved in the 5-MTHF group at week 8 versus baseline (\(P < .01\)). Delayed recall was not changed.

However, a review24 of 4 double-blind, randomized, placebo-controlled studies and a subsequent 2-year double-blind, randomized, placebo-controlled trial25 of folate with or without vitamins B₁₂ and B₆ in older patients who either were healthy or had dementia or mild-to-moderate cognitive impairment found that, although serum homocysteine concentrations were reduced, no benefits were apparent for any measures of cognition. Although evidence for the efficacy of folate in cognition is equivocal, the use of folic acid in most of these studies may be a confound. Another formulation of folate that can cross the blood-brain barrier might have shown greater benefit.

Limitations of Studies

Some of the studies discussed are limited by the use of a mixed diagnostic population, eg, those with depression, schizophrenia, and dementia. Findings may have been confounded because the focus of some studies was on depressive symptoms as opposed to MDD and subjects had concurrent diagnoses such as dementia. Studies frequently had small sample sizes or used uncommon assessment scales.

Many of the studies of folate and cognition used forms of folate that require multiple steps to cross the blood-brain barrier. Individuals with the polymorphism on the 677th coding of the MTHFR enzyme and those who take particular medications or consume alcohol might respond better to MTHF. The most active form of folate, 5-MTHF, has recently been approved in the United States as a prescription medical food for depressed patients with folate deficiency. Doses are usually 7.5 to 15 mg/d.

Measurement of peripheral folate levels may not necessarily reflect the amount of folate in the central nervous system (CNS). People with depression may have lower CNS folate level but still appear to have a normal folate level, if the peripheral folate was measured. In the future, normofolatemic people will likely constitute the majority of study populations because folate fortification is now mandatory in some foods in the industrialized world. Folic acid deficiency in itself is therefore likely to become increasingly rare, and researchers and clinicians will need to characterize
factors that might be associated with a response to folate supplementation in individuals with normal folate levels.

Safety Considerations

The studies reviewed indicate that folate is generally well tolerated. Historically, the greatest concern with folate supplementation has been its ability to mask vitamin B12 deficiency. Inadequate B12 results in anemia identical to that caused by folate deficiency; however, inadequate B12 also causes irreversible damage to the central and peripheral nervous systems. Folic acid supplementation corrects the anemia of B12 deficiency, delaying diagnosis but concealing the continuing lack of B12, thus leaving the patient vulnerable to permanent nervous system damage. However, 5-MTHF is unable to synthesize DNA and is, therefore, not expected to mask B12 deficiency.

Cancer risk has also been a concern with folate supplementation. A recent review of the evidence concluded that those claims are not well supported. The benefits of folate supplementation probably outweigh the risks of cancer. However, caution should be used in at-risk patients, such as those with a family history of colorectal cancer.

Another concern is that folate doses > 800 μg/d can result in high levels of unmetabolized serum folic acid, reducing the amount of brain L-methylfolate and leading to decreased monoamines, an outcome that potentially increases the risk of or exacerbates depression. Again, the findings are mixed, but, in individuals in whom this is a concern, 5-MTHF may be less likely to incur these risks.

CONCLUSION

Despite study limitations and some safety concerns, several folate forms appear to be well tolerated and efficacious for some individuals with MDD. Folate monotherapy may benefit certain depressed populations, and augmentation with folate may enhance antidepressant efficacy from the start of treatment or convert partial and nonresponders into responders or even into remitters. Folate has historically been used in subjects with low plasma or red blood cell folate levels, but studies suggest that some individuals with normal folate levels may also benefit, especially since peripheral folate levels may not reflect CNS folate levels. Factors associated with response in normofolatemic individuals need to be identified.

More placebo-controlled studies with rigorous methodologies and large sample sizes are needed to elucidate the roles of the different folate compounds in the treatment of MDD. The ability of different folate forms to cross the blood-brain barrier requires further investigation to determine the most efficacious doses to benefit mood. Further, clinicians need to know which depressed populations may be particularly suited to folate augmentation and whether medical or psychiatric comorbidity affects response to folate therapy. For example, depressed populations that may be appropriately treated with folate include those who are vulnerable to medication-related adverse events but might be able to tolerate folate and those who are folate-deficient or at risk of deficiency, such as elderly people who have nutritional problems, individuals with recent alcoholism, and women of childbearing age who take medications that interfere with folate metabolism.

Financial Disclosure: Dr Fava reported the following lifetime financial disclosures as of August 11, 2009: he has received research support from Abbott, Alkermes, Aspect Medical Systems, AstraZeneca, Bio Research, BrainCells Inc, Bristol-Myers Squibb, Cephalon, Clinical Trial Solutions, Eli Lilly, Forest, Ganeden, GlaxoSmithKline, Johnson &


